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Abstract
Purpose This review examines the clinical evidence showing
that imatinib can be prescribed to treat recurrence or progres-
sion of gastrointestinal stromal tumors (GIST) in patients
who interrupted first-line imatinib therapy in the adjuvant or
advanced/metastatic setting.
Methodology A literature search was performed in PubMed,
Web of Knowledge, and Google using the following keywords:
rechallenge/reinitiation/reintroduction+gastrointestinal+
imatinib and rechallenge/reinitiation/reintroduction+imatinib.
Results The evidence indicates that the reintroduction of
imatinib can benefit patients who experience GIST progres-
sion after interrupting treatment of advanced/metastatic dis-
ease, as well as patients who experience GIST recurrence after
completing prescribed neoadjuvant and/or adjuvant therapy.
Although reintroduction of imatinib may lead to suboptimal
outcomes, as evidenced by higher rates of progressive disease
compared to initial treatment, imatinib discontinuation does
not appear to favor development of imatinib resistance, leav-
ing dose escalation and third- or fourth-line imatinib treatment
as viable options for patients.
Conclusion Results indicate that after initial start and inter-
ruption of imatinib therapy, reintroduction of imatinib therapy
is efficacious and provides continued survival benefit in pa-
tients with GIST.
Keywords Gastrointestinal stromal tumor . GIST . Imatinib .
Tyrosine kinase inhibitor . Relapse . Rechallenge .
Reintroduction
Introduction
Imatinib is the only first-line targeted therapy approved to treat
patients with gastrointestinal stromal tumors (GIST), both as
adjuvant therapy following resection and in the advanced/
metastatic setting [1–3]. Imatinib has significantly improved
outcomes for patients with metastatic GIST compared to histor-
ical controls treated with traditional chemotherapy, radiation
therapy, and/or best supportive care (BSC) [4]. Disease control
ranges from 70 to 85%;median progression-free survival (PFS)
is 29months, andmedian overall survival (OS) is 57 months
[4, 5]. Unfortunately, only 3–5% of patients with unresectable
or metastatic GIST treated with imatinib experience complete
tumor response (CR), and the 3-year PFS rate is 31 % [5, 6].
More than 50 % of patients who benefit from imatinib develop
progressive disease (PD) within 2 years, which poses an im-
portant clinical problem [6].
Another clinical challenge comes from the fact that patients
sometimes opt to stop imatinib therapy due to treatment-
related adverse events (AEs) or other reasons but whether
these interruptions favor or limit emergence of drug-resistant
clones is unclear [7]. Moreover, optimal duration of adjuvant
imatinib treatment for patients with localized resected disease
remains undetermined and whether patients with recurrent
disease may benefit from reintroduction of imatinib upon
relapse later has not been extensively investigated.
Disease progression or recurrence after treatment with tradi-
tional cytotoxic anticancer chemotherapy often indicated that
treatment failed (due to resistance) and could not be used again
(e.g., in case of relapse) [8]. However, accumulating evidence
suggests that in some patients, targeted therapy with tyrosine
kinase inhibitors (TKI) can be effectively reintroduced after
prior use to control tumor growth. For example, patients with
chronic myeloid leukemia (CML) are typically treated with
daily imatinib indefinitely, unless they experience relapse or
unacceptable toxicity [9]. In the Stop Imatinib (STIM) trial,
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Mahon et al. found that molecular relapse occurred in 54 % of
patients with CML who interrupted treatment (median
follow-up, 17 months) [9]. When imatinib (400 mg/day) was
reintroduced in those patients, all of them regained complete
molecular response after a median of 3 months, regardless of
initial duration of imatinib therapy. These results suggest that
discontinuation does not lead to acquired, secondary resistance
(Box 1) and that imatinib reintroduction is feasible in patients
with CML [9]. Herein, we review the evidence supporting the
reintroduction of imatinib in patients with GIST who were
previously treated with imatinib in the adjuvant or advanced/
metastatic setting. The data indicate that interruption of
imatinib does not preclude its subsequent use after GIST
recurrence or progression.
Box 1: Primary versus secondary resistance
○ Primary resistance is characterized by a lack of response to treatment
and concomitant disease progression [1, 20]
• In GIST, primary resistance to TKI usually occurs within 3–6 months
of treatment initiation
• Mutated KIT exon 9 or PDGFRA and wild-type GIST are most often
responsible for primary resistance
○ Secondary resistance occurs after patients responded to treatment for at
least 6 months [20]
• In GIST, secondary resistance to TKI usually develops between 6–
24 months
• Patients with primary mutations in PDGFRA rarely experience
secondary resistance
• Potential causes include clonal selection/evolution, gene amplifica-
tion, increased transport, and mutations in other genes
○Reintroduction of the original treatment (e.g., TKI) is possible in case of
secondary resistance, but not primary resistance
GIST, gastrointestinal stromal tumor; PDGFRA, platelet-
derived growth factor receptor alpha; TKI, tyrosine kinase
inhibitors
Reintroduction of Imatinib in the Advanced/Metastatic
Setting
For patients with advanced/metastatic GIST, current National
Comprehensive Cancer Network (NCCN) guidelines recom-
mend that imatinib therapy be continued indefinitely or until
disease progression [1]. The NCCN guidelines also caution
that discontinuing imatinib/TKI therapy may accelerate the
pace of disease progression [1].
Because imatinib-related AEs are typically mild to moder-
ate and manageable, chronic administration for GIST is gen-
erally feasible. However, even mild AEs may prompt patients
to request a treatment interruption/holiday if experienced
chronically [7]. The phase III BFR14 trial thus investigated
whether imatinib may be stopped in patients whose disease is
controlled [10]. Unfortunately, data indicated that for patients
who achieved disease control for 1 year while on imatinib
treatment, subsequent interruption of imatinib was associated
with a major risk of disease progression: median time to pro-
gression (TTP) was 6 months and more than 70 % of the
patients had relapsed 1 year after discontinuing imatinib [10].
Importantly, 92 % of the patients who reintroduced imatinib
during GIST progression regained tumor control [10].
Similarly, the BFR14 study showed rapid GIST progression
when patients stopped imatinib after 1, 3, or 5 years of treat-
ment with disease control (Table 1) [7]. Results also showed
that patients who restarted imatinib regained tumor control
(Table 1), indicating that imatinib can be reintroduced upon
disease progression. Interruption of imatinib does not prevent
subsequent use to control GIST [7]. Indirectly, these results also
suggest that imatinib reintroduction can be beneficial in patients
who interrupt treatment of advanced/metastatic GIST due to
AEs (or other personal reasons) but are not necessarily resistant
to imatinib. However, the high relapse rate suggests that it is not
advisable to discontinue imatinib therapy.
Reintroduction of Imatinib after Completion of Adjuvant
Therapy
DeMatteo et al. [11] were the first to report rapid/early disease
recurrence after discontinuation of imatinib in the adjuvant
setting. In the phase III American College of Surgeons
Oncology Group (ACOSOG) Z9001 trial, patients who had
complete resection of primary GIST ≥3 cm were randomized
to receive imatinib 400 mg/day (N=359) or placebo (N=354).
After a follow-up of 19.7 months, 20 % of patients in the
placebo group had either tumor recurrence or died versus 8 %
in the imatinib group. Imatinib was well tolerated and improved
the 1-year recurrence-free survival rate (RFS, 98 %; 95 %
confidence interval (CI), 96–100) compared with placebo
(RFS, 83 %; 95 % CI, 78–88). The hazard ratio was 0.35
(95%CI, 0.22–0.53; p<0.0001). Notably, the rate of recurrence
increased in the imatinib group after approximately 18 months
(i.e., 6 months after completion of therapy), suggesting that it
Table 1 Reintroduction of imatinib can rescue progression of advanced/
metastatic GIST that occurs following treatment interruption







Patients with tumor control
after imatinib reintroduction (%)
92 100 86
Median follow-up (months) 74 47 18
Adapted fromBlay et al. by the permission of Oxford University Press [7]
GIST gastrointestinal stromal tumor, NR not reached, PFS progression-
free survival
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may not be advisable to interrupt imatinib treatment following
GIST resection [11].
In the phase III Scandinavian Sarcoma Group of the
Arbeitsgemeinschaft Internistische Onkologie (SSGXVIII/
AIO) trial, patients with a high risk of recurrence following
GIST resection were randomly assigned to receive 12 months
(N=199) or 36 months (N=198) of imatinib 400 mg/day. At a
median follow-up of 54 months, disease had recurred in
27.1 % of patients in the 1-year group versus 13.6 % of
patients in the 3-year group. These patients were then re-
treated with imatinib at 100 mg/day (N=3), 400 mg/day
(N=71), 600 mg/day (N=1), or 800 mg/day (N=6) [12].
Clinical benefit was observed in 84.8 % of patients and was
not different between the 1- and 3-year arms (p=0.385):
32.6 % had CR, 30.4 % had partial response (PR), and
21.7 % had stable disease (SD). Similarly, median TTP
(35.7 months) was not different between the two arms
(p=0.289) [12]. These results suggest that more than 84 %
of the patients who completed adjuvant imatinib and received
imatinib as first-line treatment for recurring GIST responded
to imatinib reintroduction, independent of the length of prior
imatinib therapy in the adjuvant setting (1 versus 3 years) [12,
13]. Moreover, the response rate did not differ markedly
from that of imatinib-naive patients, regardless of the
duration of prior adjuvant imatinib treatment [12, 13].
Based on these data, NCCN guidelines recommend at
least 1 year of imatinib treatment following resection of
primary GIST and at least 3 years of therapy for pa-
tients at high risk of recurrence [1].
In the SSGXVIII/AIO trial, Joensuu et al. [13] also showed
that only 2 % (4/199) and 6 % (12/198) of the patients
developed GIST recurrence while receiving adjuvant imatinib
for 12 and 36 months, respectively, compared with 40 % of
patients treated with surgery alone (historical controls with a
median follow-up of 24 months) [14]. These results suggest
that acquired resistance to adjuvant imatinib was infre-
quent, especially since both arms included patients with
mutations known to be less sensitive or resistant to imatinib
(e.g., platelet-derived growth factor receptor alpha [PDGFRA]
D842V) [13].
In a case report, Kang [15] described a patient who was at
high risk of recurrence (after undergoing complete resection of
a primary GIST) and received 2 years of imatinib therapy. Ten
months after completion of the adjuvant treatment, a comput-
ed tomographic (CT) scan revealed disease recurrence. The
patient was re-treated with imatinib 400 mg/day and, 1 month
later, a PR was observed (by Response Evaluation Criteria In
Solid Tumors [RECIST]) with a 43 % decrease in tumor size
and mild AEs (grade 1 edema, anemia, and fatigue). The PR
was maintained for 33 months before the disease progressed
again. The patient was then treated with a dose escalation to
800 mg/day and was still being monitored at the time of
publication.
Overall, these results suggest that sensitivity to imatinib is
not compromised by prior exposure to adjuvant imatinib and
that imatinib reintroduction remains an option for patients
who experience GIST recurrence after completing the recom-
mended adjuvant treatment (Table 2).
Reintroduction of Imatinib after Neoadjuvant Therapy
Although imatinib is not approved by the US Food and Drug
Administration for this indication, the NCCN mentions that
imatinib may be used as neoadjuvant prior to surgery to
downstage a tumor and improve the probability of R0 resec-
tion and/or reduce morbidity (Fig. 1) [1]. Many investigations
have shown the benefits of perioperative imatinib. In a study of
29 patients who received neoadjuvant imatinib (median dura-
tion, 8.5 months) for borderline resectable and locally advanced
GIST, the overall response rate was 79.3 %: 62.5 % of the
patients initially deemed to have unresectable GIST underwent
surgery and 90.5 % of those originally scheduled for surgery
had a less extensive one [16]. Following resection, 86.2 %
of patients received adjuvant imatinib and, after a mean
follow-up of 10 months, locoregional recurrence and distant
metastasis were found in one (4 %) and two (8 %) patients,
respectively [16].
In another study, 19 patients with locally advanced GIST
received neoadjuvant imatinib 400 mg/day for ≥12 weeks (up
to 6 months in cases of suboptimal response). Treatment was
stopped 5–7 days prior to surgery and resumed afterward for
2 years (or until response) [17]. Preoperative imatinib allowed
68.4 % of the patients to achieve PR with R0 resection,
whereas 31.6 % achieved SD with R1 resection. At a 2-year
follow-up, there was no PD or death, and AEs were minimal
[17]. Similarly, Jakob et al. followed up 36 patients with
primary rectal GIST who underwent surgery in the context
of neoadjuvant and/or adjuvant imatinib [18]. Results showed
that the patients treated with perioperative imatinib had im-
proved disease-free survival (DFS; p<0.01) and OS (p=0.03).
Importantly, patients who received perioperative imatinib also
had a higher rate of R0 resection compared with those who
received adjuvant imatinib only (p=0.02) [18].
In a longer-term analysis, 53 patients with primary GIST
≥5 cm (group A, N=31) or resectable metastatic/recurrent
GIST ≥2 cm (group B, N=22) received neoadjuvant imatinib
600 mg/day for approximately 2 months and adjuvant therapy
for 2 years [19]. Median TTP was not reached in group A and
was 4.4 years in group B; 5-year DFS and OS rates were 57 and
77 % in group A versus 30 and 68 % in group B, respectively
[19]. Moreover, imatinib was well tolerated.
Overall, these results demonstrate that perioperative imatinib
improves resectability and survival outcomes for patients. The
results also suggest that prior exposure to neoadjuvant imatinib
does not compromise its efficacy as postsurgery adjuvant treat-
ment to prevent recurrence.
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Reintroduction of Imatinib after Treatment Interruption
and Development of Drug Resistance
Resistance can be primary or secondary (Box 1). Primary
resistance is defined by an early lack of response (typically
within 3 to 6 months) and disease progression. It is often
associated with mutations in KIT exon 9 or PDGFRA exon
18 (e.g., D842V) but is also found in wild-type GIST (i.e.,
GIST without known mutations in KIT or PDGFRA) [1, 20].
In contrast, secondary resistance generally occurs 6 to
24 months after patients’ initial response to the treatment and
is rarely seen in patients with PDGFRA mutations [20]. By
definition, only secondary resistance is potentially amenable to
imatinib reintroduction.
Clonal selection after acquisition of new KIT mutations,
gene amplification, increased drug transport, and mutations in
genes other than KIT and PDGFRA have been described to
explain secondary resistance [1, 20]. However, results from
CML studies suggest that imatinib interruption does not pro-
mote survival of drug-resistant clones and development of
secondary resistance [9]. Whether this is the case in GIST
has not been extensively studied, but there is evidence
suggesting that the recurrence or progression during/after
imatinib therapy does not necessarily equate with complete
resistance to imatinib.
Lee et al. [21] studied 58 Korean patients with advanced
GIST who had achieved at least SD while taking imatinib.
After a median treatment time of 11.9 months, 24.1 % of
patients interrupted imatinib; 17.9 months later (median
follow-up), 64.3 % of patients who interrupted imatinib had
developed PD, with a median PFS of 10.0 months. Median
PFS from the time of imatinib initiation was 21.8 months
(95 % CI, 17.3–26.3) in the interruption group but was not
reached in the continuation group (p=0.029). Importantly,
88 % of the patients achieved disease control again following
imatinib reintroduction, suggesting that in patients with
nonprogressing GIST, it is possible to temporarily interrupt
treatment when clinically warranted [21].
Another study by Blay et al. [10] indicated that 92 % of
patients who interrupted and then restarted imatinib treatment
after experiencing GIST progression experienced tumor re-
sponse or SD (Fig. 2). However, this particular study was not
powered to support this endpoint, and an increased risk of
resistance after reintroduction could not be excluded. In the
prospective, multicenter, phase III BFR14 study, patients with
advanced, nonprogressing GIST treated with imatinib were
Table 2 Reintroduction of imatinib can be beneficial for patients who experience GIST recurrence following completion of prescribed adjuvant therapy
Trial/study Treatment (years) N Follow-up (months) Recurrence (%) TTP (months) Response to reintroduction
ACOSOG Z9001 [11] Placebo (1) 354 19.7 20 NA NA
Imatinib (1) 359 8 ~6
SSGXVIII/AIO [12, 13] Imatinib (1) 199 54 27.1 35.7 84.8 % of patients
Imatinib (3) 198 13.6 35.7
Kang [15] Imatinib (2) 1 Ongoing Yes 10 43 % smaller tumor 1 month latera
NA not applicable, TTP time to progression following imatinib cessation
a The patient experienced recurrence 3 months following reintroduction of imatinib 400 mg/day and was being monitored after dose escalation to
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7 events in 25 patients
1-year PFS 92% (95% CI 72–98)
2-year PFS 80% (95% CI 58–91)
Interruption group
21 events in 25 patients
1-year PFS 32% (95% CI 15–50)





Fig. 2 PFS in patients with advanced, nonprogressing GIST randomized
to interruption or continuation of imatinib treatment at 3 years. (Reprinted
from Blay et al. by the permission of Oxford University Press [7])
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randomized to the interruption or continuation arm after 1 year
(N=32 versus 28), 3 years (N=25 versus 25), or 5 years (N=14
versus 13) of imatinib treatment (400 mg/day), respectively
[22, 23]. After 18 months, 76 % (54/71) of patients in the
interruption arm restarted imatinib, 94.4 % of whom had PD
[23]. Imatinib reintroduction allowed tumor control in 94 % of
those patients, regardless of the length of prior imatinib
therapy [22, 23]. However, only 41 and 56 % of patients
who initially experienced CR and PR achieved a new CR
and PR as best response, respectively, when imatinib was
reintroduced (Table 3) [23]. Imatinib interruption had no
effect on OS, but median PFS was shorter in the interruption
arm than the continuation arm (Table 1): 7 versus 29 months
(1 year, p≤0.0001), 9 months versus not reached (3 years,
p<0.0001), and 13 months versus not reached (5 years), re-
spectively [7, 22]. These results suggest that the emergence of
secondary resistance to imatinib decreases over time [7]. In
addition, imatinib interruption had no effect on the time to
secondary resistance, suggesting that it does not affect clonal
selection of tumor cells in GIST. However, these results
should be interpreted with caution because of the small num-
ber of patients in the study [7].
Overall, results from theBFR14 trial showed that interruption
of imatinib therapy in patients with advanced disease correlates
with a high risk of GIST progression and that reintroduction
of imatinib remains an option for these patients. Imatinib
interruption did not promote survival of drug-resistant clones
or development of secondary resistance (Box 1), and
reintroduction of imatinib could restore tumor control in most
patients although at a lower level of efficacy than the initial
therapy [7, 22, 23]. From a broader perspective, these results
suggest that because imatinib is a TKI, it does not necessarily
eradicate GIST tumor cells, resulting in persistent disease and
the need for continuous suppression of the kinase activity of
KIT or PDGFRA to achieve the best clinical outcomes [5].
Accordingly, these results emphasize the need to educate
patients about the risk of interrupting imatinib therapy.
Dose escalation of Imatinib after Failure of Initial Treatment
A few studies have shown that dose escalation to 600 or
800 mg/day may improve survival after patients experience
PD on 400 mg/day [4, 24, 25], consistent with the idea that
progression does not necessarily imply complete resistance to
therapy. In a study of 47 evaluable patients with advanced
GISTwho experienced disease progression while treated with
imatinib 400 mg/day, Li et al. [24] reported that 40.4 %
achieved disease control when treated with imatinib 600 mg/
ml: 6.4 % (3/47) had PR and 34.0 % (16/47) had SD [24].
Median PFS for all patients was 17 weeks (95 % CI, 3.9–
30.1), dose escalation to 600 mg/day was well tolerated, and
the most frequent AEs were edema and fatigue, reported by
73.1 % of the patients. However, further dose escalation to
800 mg/day in patients whose GIST progressed while on
imatinib 600 mg/day (14/47 or 29.7 %) was not effective [24].
In the phase III European Organization for Research and
Treatment of Cancer/Italian Sarcoma Group/Australasian
Gastrointestinal Trials Group (EORTC-ISG-AGITG) trial,
247 patients with advanced GIST who received imatinib
400 mg/day were allowed to receive 800 mg/day upon disease
progression. Of the 241 patients available for follow-up, 55 %
(133) crossed over to the high-dose arm after exhibiting PD
[25]. At the time of analysis, 2.3 % of patients had PR, 27.1 %
had SD, and median PFS after crossover was 81 days.
Overall, imatinib-related toxicities (mostly anemia and fatigue)
remained easily manageable, and dose reductions after crossing
over to the high-dose arm were necessary in <8 % of the cases
[25]. In the phase III S0033 trial, 746 patients with advanced
GISTwere randomized to receive 400mg of imatinib once or
twice daily, and those who progressed on 400 mg/day
were allowed to cross over to the high-dose arm [26].
Of all patients whose dose was escalated to 400 mg twice
daily, 33 % achieved PR or SD. Imatinib was relatively well
tolerated, although serious AEs were more frequent in the
high-dose arm (grade 3–5, 63 %) than the low-dose arm (grade
3–5, 43 %) [26].
Altogether, these results indicate that dose escalation
is a feasible and reasonable option in patients with advanced,
progressing GIST, despite evidence of increased toxicity.
Furthermore, these results support the idea that GIST progres-
sion does not automatically mean resistance to imatinib.
Reintroduction of Imatinib in Third- or Fourth-line Settings
Although up to 80% of the patients with GISTwill respond to
imatinib treatment, 10–20 % will exhibit disease progression
or recurrence associated with primary (early) resistance within
3–6 months of therapy initiation [20, 27]. In addition, 40–
50 % of the patients will develop secondary (delayed or
acquired) resistance and disease progression or recurrence
after 6–24 months of therapy [27]. Several studies suggest
Table 3 Reintroduction of imatinib restores control of advanced GIST,
but with a lower efficacy than the initial treatment [23]








Best response prior to imatinib
interruption
33.3 49 17.6
Best response following imatinib
reintroduction
(relative to responding patients)
41.2 56 NR
Best response following imatinib
reintroduction
(relative to total patients)
13.7 27.5 NR
CR complete response, NR not reported, PR partial response, SD stable
disease
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that reintroduction of imatinib may be effective in GIST
patients who develop resistance to first-line imatinib.
In a retrospective analysis, 223 patients with imatinib- and
sunitinib-resistant metastatic GISTwere treated with third-line
nilotinib (N=67), sorafenib (N=55), or other drugs (N=16).
Alternatively, patients received imatinib plus another agent
(N=27), BSC (N=18), or were re-treated with imatinib alone
(N=40) [28]. After adjustment for prognostic factors, results
showed that nilotinib and sorafenib provided the best median
PFS (4.1 versus 4.9 months, respectively) and median OS (11.8
versus 10.7 months, respectively) compared with BSC (PFS,
2.1months, p=0.001; OS, 2.4months, p<0.0001). Re-treatment
with imatinib alone was also associated with improved
OS (median, 7.5 months) compared with BSC (p<0.0001)
[28]. Similarly, reintroduction of imatinib in combination with
other agents (doxorubicin, gemcitabine, cyclophosphamide,
sirolimus, or bevacizumab) also improved OS (median,
8.7 months) compared with BSC (p<0.0001), but how it com-
pares to imatinib alone was not reported [28]. Reintroduction of
imatinib thus represents a feasible option for patients with GIST
that initially responded before developing secondary resistance
(Box 1) and progressing on second-line therapies or becoming
intolerant to other targeted therapies [29].
As mentioned previously, the most likely explanation for
the response to imatinib reintroduction is that re-expansion of
sensitive tumor clones occurs after the selection pressure is
removed [29]. Results from one preclinical study suggest that
autophagy, an evolutionarily conserved, lysosomal-driven
process of controlled self-digestion, may contribute to the
survival of GIST cells during imatinib-induced quiescence
[30]. Gupta et al. indeed showed that autophagy is induced in
GIST cell lines treated with imatinib in vitro and that inhibiting
autophagy promotes cell death. Treatment of GIST-T1 and
GIST882 cells with imatinib caused a specific three- to fivefold
decrease in the S+G2/M fraction, with a matching increase in
the G0/G1 fraction, indicating cell cycle arrest. In contrast,
imatinib-resistant GIST-T1R cells did not undergo cell cycle
arrest upon treatment [30]. Immunofluorescence and electron
microscopy also showed formation of autophagosomes in
imatinib-treated GIST-T1 cells, an effect that was reversed by
RNA interference-mediated depletion of known autophagy
regulators (ATG7 and ATG12). Importantly, analysis of tissue
samples from patients treated with imatinib for 3, 5, or 7 days
before resection revealed autophagosomes in responsive pa-
tients who received imatinib for 7 days compared with the
shorter treatments [30]. Overall, results from preclinical exper-
iments thus suggest that GIST cells could survive imatinib
treatment by becoming quiescent and activating an autophagy-
dependent survival mechanism.
Another preclinical study suggested instead that the pres-
ence of KITlowCD44+CD34+ progenitor cells (or stem cells)
that do not depend on KIT for survival explains the presence of
residual, persistent, imatinib-refractory cells, and, consequently,
the eventual recurrence/progression of GIST [31]. Regardless
Inclusion criteria:
• Prior benefit from imatinib for ≥6 months
• Disease progressed despite prior imatinib (400 mg/day) 
 and sunitinib treatment
• ECOG performance status 0 to 3
• Adequate bone marrow function
• Adequate renal and hepatic function
• Life expectancy >12 weeks in the absence of 
 any intervention
• No other malignant disease apart from non-melanocytic 
 skin cancer or carcinoma in situ of the cervix or any 
 other cancer, except when treated with curative intent 
 >5 years previously without evidence of relapse
• Written, informed consent
Exclusion criteria:
• Medical and/or psychiatric conditions that compromise 
 the patients’ ability to give informed consent or complete 
 protocol
• History of noncompliance
• Last dose of radiotherapy received within 4 weeks of 
 the study start, except palliative radiotherapy
• GI obstruction or active GI bleeding
• Myocardial infarction within 6 months of the study start, 
 or uncontrolled hypertension, congestive heart failure, 
 or unstable angina
• Evidence of severe or uncontrolled systemic disease
• Female patients who are pregnant or breast-feeding 
 (negative test within 1 week of starting imatinib required)
Imatinib arm:
• Patients will receive imatinib 400 mg/day (4 × 100-mg 
 tablets) once daily with food until disease progression, 
 unacceptable toxicity, or withdrawal of consent
Placebo arm:
• Patients will receive placebo 400 mg/day (4 × 100-mg 
 tablets) once daily with food until disease progression 
 or withdrawal of consent
Endpoints:
•  Primary endpoint: progression-free survival (time-frame: ≤12 weeks)
• Secondary endpoint: disease control rate, i.e., complete  or partial response and stable disease (time-frame: ≤12 weeks) 
Patients 18 years and older with advanced/metastatic KIT-positive GIST (NCT01151852)
Fig. 3 Diagram of the double-blind, randomized, phase III RIGHT trial to compare clinical outcomes following reintroduction of imatinib or placebo in
patients with advanced/incurable GIST who benefited from prior imatinib but progressed on both imatinib and sunitinib
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of the mechanistic rationale for imatinib reintroduction, the
NCCN recommends considering reintroduction of a previously
tolerated and effective TKI for palliation of symptoms in pa-
tients with progressing GIST, despite prior response to imatinib
and sunitinib [1]. According to NCCN guidelines, therapy
should be continued for as long as patients can tolerate it as
part of BSC.
Currently, a randomized, placebo-controlled, phase III trial
(Rechallenge of Imatinib in GIST Having no effective
Treatment [RIGHT]) is underway in Korea to compare out-
comes following reintroduction of imatinib therapy versus
placebo in patients with advanced/incurable GIST who ini-
tially responded but then progressed on imatinib and sunitinib
[ClinicalTrials.gov identifier: NCT01151852] (Fig. 3). The
study was expected to be completed in March 2013 and
should provide additional insights on the effect of imatinib
reintroduction on PFS and disease control rate. Several clini-
cal studies are also completed or underway to investigate
the efficacy of imatinib in combination with other drugs
(e.g., everolimus [32], doxorubicin [33], and perifosine
[ClinicalTrials.gov identifier: NCT00455559]) in treating
metastatic GIST. Hopefully, these combinations will provide
new options to re-treat tumors that previously responded to a
single-agent TKI.
Conclusions
Current evidence indicates that imatinib potently inhibits the
activity of KIT and PDGFRA kinases, but imatinib treatment
may not completely eliminate GIST cells. Tumor control may
thus depend on chronic, continuous suppression of imatinib-
sensitive tumor cells with imatinib to prevent GIST recurrence
or progression [7, 15]. However, treatment holidays and dis-
continuations are not uncommon in advanced and adjuvant
settings in GIST. These voluntary interruptions most often
require patients to reinitiate therapy, and studies indicate that
imatinib reintroduction can be effective. However, response to
reintroduction may be suboptimal, and interruption of imatinib
treatment should thus be avoided.
Overall, reintroduction of imatinib in patients with
advanced/metastatic GISTcan provide additional clinical ben-
efits and improve patients’ outcomes upon disease progres-
sion. Similarly, imatinib reintroduction offers clinical benefits
in patients with GIST who completed adjuvant treatment and
then experienced recurrence, independent of the length of prior
adjuvant therapy. However, in both settings, reintroduction of
imatinib after treatment interruption is associated with a lower
efficacy and a higher rate of progressive disease, compared
with initial therapy, suggesting that the tumor response to
imatinib re-treatment may be suboptimal. Prior exposure to
neoadjuvant imatinib did not appear to compromise the efficacy
of postsurgical treatment either, which could be because the
time elapsed between neoadjuvant and adjuvant treatments is
typically short (few days).
Based on clinical evidence, treatment interruption does not
appear to affect the emergence of imatinib-resistant clones,
which likely explains why imatinib reintroduction can also
provide clinical benefit as third- or fourth-line therapy in
patients with GIST. Likewise, the apparent lack of effect of
imatinib on emergence of resistance probably explains why
dose escalation can be effective in controlling GIST growth in
some patients.
In summary, the literature suggests that interruption of
imatinib treatment in the adjuvant or metastatic setting neither
compromises sensitivity to imatinib nor precludes its subse-
quent use to treat GIST recurrence or progression. Even
though discontinuing or interrupting treatment is not recom-
mended, due to increased risk of disease recurrence or pro-
gression, reintroduction of imatinib can lead to additional
clinical benefits for patients with GIST and thus remains a
feasible option for them in the adjuvant or advanced/
metastatic setting.
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